Literature DB >> 18048501

Conditional expression of a Gi-coupled receptor in osteoblasts results in trabecular osteopenia.

J Peng1, M Bencsik, A Louie, W Lu, S Millard, P Nguyen, A Burghardt, S Majumdar, T J Wronski, B Halloran, B R Conklin, R A Nissenson.   

Abstract

G protein-coupled receptors (GPCRs) coupled to activation of Gs, such as the PTH1 receptor (PTH1R), have long been known to regulate skeletal function and homeostasis. However, the role of GPCRs coupled to other G proteins such as Gi is not well established. We used the tet-off system to regulate the expression of an activated Gi-coupled GPCR (Ro1) in osteoblasts in vivo. Skeletal phenotypes were assessed in mice expressing Ro1 from conception, from late stages of embryogenesis, and after weaning. Long bones were assessed histologically and by microcomputed tomography. Expression of Ro1 from conception resulted in neonatal lethality that was associated with reduced bone mineralization. Expression of Ro1 starting at late embryogenesis resulted in a severe trabecular bone deficit at 12 wk of age (>51% reduction in trabecular bone volume fraction in the proximal tibia compared with sex-matched control littermates; n = 11; P < 0.01). Ro1 expression for 8 wk beginning at 4 wk of age resulted in a more than 20% reduction in trabecular bone volume fraction compared with sex-matched control littermates (n = 16; P < 0.01). Bone histomorphometry revealed that Ro1 expression is associated with reduced rates of bone formation and mineral apposition without a significant change in osteoblast or osteoclast surface. Our results indicate that signaling by a Gi-coupled GPCR in osteoblasts leads to osteopenia resulting from a reduction in trabecular bone formation. The severity of the phenotype is related to the timing and duration of Ro1 expression during growth and development. The skeletal phenotype in Ro1 mice bears some similarity to that produced by knockout of Gs-alpha expression in osteoblasts and thus may be due at least in part to Gi-mediated inhibition of adenylyl cyclase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18048501      PMCID: PMC2275363          DOI: 10.1210/en.2007-0235

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  31 in total

1.  A single mutation in the 5-HT4 receptor (5-HT4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL).

Authors:  Sylvie Claeysen; Lara Joubert; Michèle Sebben; Joël Bockaert; Aline Dumuis
Journal:  J Biol Chem       Date:  2002-11-18       Impact factor: 5.157

Review 2.  The regulation of adenylyl cyclase by receptor-operated G proteins.

Authors:  A Levitzki; A Bar-Sinai
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

3.  Regulating DeltaFosB expression in adult Tet-Off-DeltaFosB transgenic mice alters bone formation and bone mass.

Authors:  N A Sims; G Sabatakos; J-S Chen; M B Kelz; E J Nestler; R Baron
Journal:  Bone       Date:  2002-01       Impact factor: 4.398

4.  Identification of a novel extracellular cation-sensing G-protein-coupled receptor.

Authors:  Min Pi; Pieter Faber; George Ekema; P David Jackson; Anthony Ting; Nancy Wang; Michelle Fontilla-Poole; Robert W Mays; Kurt R Brunden; John J Harrington; L Darryl Quarles
Journal:  J Biol Chem       Date:  2005-09-30       Impact factor: 5.157

Review 5.  Engineering the melanocortin-4 receptor to control G(s) signaling in vivo.

Authors:  Supriya Srinivasan; Christian Vaisse; Bruce R Conklin
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

6.  The cyclic-AMP antagonist adenosine-3',5'-cyclic monophosphosphorothioate, RP-isomer inhibits parathyroid hormone induced bone resorption, in vitro.

Authors:  O Ljunggren; S Ljunghall
Journal:  Biochem Biophys Res Commun       Date:  1993-06-30       Impact factor: 3.575

7.  Role of dual signal transduction systems in the stimulation of bone resorption by parathyroid hormone-related peptide. The direct involvement of cAMP-dependent protein kinase.

Authors:  H Kaji; T Sugimoto; M Fukase; K Chihara
Journal:  Horm Metab Res       Date:  1993-08       Impact factor: 2.936

8.  Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter.

Authors:  P A Furth; L St Onge; H Böger; P Gruss; M Gossen; A Kistner; H Bujard; L Hennighausen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

9.  PTH differentially regulates expression of RANKL and OPG.

Authors:  John C Huang; Takeshi Sakata; Laura L Pfleger; Margaret Bencsik; Bernard P Halloran; Daniel D Bikle; Robert A Nissenson
Journal:  J Bone Miner Res       Date:  2003-12-16       Impact factor: 6.741

10.  Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone.

Authors:  Daniel D Bikle; Takeshi Sakata; Colin Leary; Hashem Elalieh; David Ginzinger; Clifford J Rosen; Wesley Beamer; Sharmila Majumdar; Bernard P Halloran
Journal:  J Bone Miner Res       Date:  2002-09       Impact factor: 6.741

View more
  25 in total

Review 1.  Remote control of neuronal signaling.

Authors:  Sarah C Rogan; Bryan L Roth
Journal:  Pharmacol Rev       Date:  2011-03-17       Impact factor: 25.468

2.  Assessing the osteoblast transcriptome in a model of enhanced bone formation due to constitutive Gs-G protein signaling in osteoblasts.

Authors:  Lalita Wattanachanya; Liping Wang; Susan M Millard; Wei-Dar Lu; Dylan O'Carroll; Edward C Hsiao; Bruce R Conklin; Robert A Nissenson
Journal:  Exp Cell Res       Date:  2015-02-20       Impact factor: 3.905

3.  Ligand-mediated activation of an engineered gs g protein-coupled receptor in osteoblasts increases trabecular bone formation.

Authors:  Edward C Hsiao; Susan M Millard; Alyssa Louie; Yong Huang; Bruce R Conklin; Robert A Nissenson
Journal:  Mol Endocrinol       Date:  2010-02-11

Review 4.  Engineering GPCR signaling pathways with RASSLs.

Authors:  Bruce R Conklin; Edward C Hsiao; Sylvie Claeysen; Aline Dumuis; Supriya Srinivasan; John R Forsayeth; Jean-Marc Guettier; W C Chang; Ying Pei; Ken D McCarthy; Robert A Nissenson; Jürgen Wess; Joël Bockaert; Bryan L Roth
Journal:  Nat Methods       Date:  2008-08       Impact factor: 28.547

5.  Constitutive protein kinase A activity in osteocytes and late osteoblasts produces an anabolic effect on bone.

Authors:  Richard S Kao; Marcia J Abbott; Alyssa Louie; Dylan O'Carroll; Weidar Lu; Robert Nissenson
Journal:  Bone       Date:  2013-04-10       Impact factor: 4.398

6.  Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors.

Authors:  Georgia M Alexander; Sarah C Rogan; Atheir I Abbas; Blaine N Armbruster; Ying Pei; John A Allen; Randal J Nonneman; John Hartmann; Sheryl S Moy; Miguel A Nicolelis; James O McNamara; Bryan L Roth
Journal:  Neuron       Date:  2009-07-16       Impact factor: 17.173

7.  Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass.

Authors:  Edward C Hsiao; Benjamin M Boudignon; Wei C Chang; Margaret Bencsik; Jeffrey Peng; Trieu D Nguyen; Carlota Manalac; Bernard P Halloran; Bruce R Conklin; Robert A Nissenson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-22       Impact factor: 11.205

8.  PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells.

Authors:  Keith R Shockley; Oxana P Lazarenko; Piotr J Czernik; Clifford J Rosen; Gary A Churchill; Beata Lecka-Czernik
Journal:  J Cell Biochem       Date:  2009-02-01       Impact factor: 4.429

9.  Serum Amyloid A3 Secreted by Preosteoclasts Inhibits Parathyroid Hormone-stimulated cAMP Signaling in Murine Osteoblasts.

Authors:  Shilpa Choudhary; Alexandra Goetjen; Thomas Estus; Christian E Jacome-Galarza; Hector L Aguila; Joseph Lorenzo; Carol Pilbeam
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

10.  Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors.

Authors:  Charles D Nichols; Bryan L Roth
Journal:  Front Mol Neurosci       Date:  2009-10-23       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.